Ibrutinib significantly inhibited Bruton’s tyrosine kinase (BTK) phosphorylation,in-vitro proliferation and enhanced overall survival in a preclinical Burkitt lymphoma (BL) model

Pediatric and adult patients with recurrent/refractory Burkitt lymphoma (BL) continue to have poor outcomes, emphasizing the need for newer therapeutic agents. Bruton’s tyrosine kinase (BTK) is activated following B-cell receptor stimulation and in part regulates normal B-cell development. Ibrutinib...

पूर्ण विवरण

में बचाया:
ग्रंथसूची विवरण
में प्रकाशित:Oncoimmunology
मुख्य लेखकों: Chu, Yaya, Lee, Sanghoon, Shah, Tishi, Yin, Changhong, Barth, Matthew, Miles, Rodney R., Ayello, Janet, Morris, Erin, Harrison, Lauren, Van de Ven, Carmella, Galardy, Paul, Goldman, Stanton C., Lim, Megan S., Hermiston, Michelle, McAllister-Lucas, Linda M., Giulino-Roth, Lisa, Perkins, Sherrie L., Cairo, Mitchell S.
स्वरूप: Artigo
भाषा:Inglês
प्रकाशित: Taylor & Francis 2018
विषय:
Original Research
ऑनलाइन पहुंच:https://ncbi.nlm.nih.gov/pmc/articles/PMC6287791/
https://ncbi.nlm.nih.gov/pubmed/30546948
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1080/2162402X.2018.1512455
टैग : टैग जोड़ें
कोई टैग नहीं, इस रिकॉर्ड को टैग करने वाले पहले व्यक्ति बनें!

समान संसाधन